Cadila Pharmaceuticals Unveils Reformulated Vasograin EC

A Trusted Migraine Relief Now Manufactured at a US FDA-Approved Facility

India

healthysoch

Ahmedabad/Chandigarh, April 08, 2025:

Cadila Pharmaceuticals is proud to introduce Vasograin EC, a reformulated version of Vasograin with a USFDA-approved formulation. A widely trusted solution for migraine relief, now manufactured in a US FDA-approved facility that adheres to stringent global standards, highlights our unwavering commitment to providing trusted & quality migraine relief solutions.

“At Cadila Pharmaceuticals, Care continues to improving patient outcomes by ensuring our medications meet the highest regulatory and quality benchmarks.

Vasograin EC is formulated to deliver rapid and long-lasting migraine relief. Its reduced tablet size enhances patient compliance, comfort, and adherence, empowering individuals to regain control of their daily lives.

As demand for effective migraine management continues to rise, Cadila Pharmaceuticals remains at the forefront, offering innovative and accessible healthcare solutions.

Over the last two years, Vasograin EC has achieved an impressive 42% growth, further cementing its position as the preferred choice for individuals seeking effective management of acute and prolonged migraine attacks. With its proven efficacy and reliability, Vasograin EC continues to lead the anti-migraine market, holding the No.1 position in the ergotamine segment with an outstanding 84% market share.

To date, over 400 crore Vasograin tablets have been sold through a network of more than 2 lakh retailers, reflecting its widespread trust and acceptance among patients and healthcare professionals.